References

  1. National Heart Lung and Blood Institute. “What is idiopathic pulmonary fibrosis?” Available at: www.nhlbi.nih.gov/health/health-topics/topics/ipf/. Accessed June 29, 2012.
  2. Raghu G, Collard HR, Egan JJ, et al. “An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.” Am J Respir Crit Care Med 2011;183:788–824.
  3. King TE Jr. “Clinical advances in the diagnosis and therapy of the interstitial lung diseases.” Am J Respir Crit Care Med 2005;172:268–279.
  4. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. “Incidence and prevalence of idiopathic pulmonary fibrosis.” Am J Respir Crit Care Med 2006;174:810–816.
  5. Navaratnum V, Fleming KM, West J, et al. “The rising incidence of idiopathic pulmonary fibrosis in the UK.” Thorax 2011;66:462–467.
  6. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. “Mortality from pulmonary fibrosis increased in the United States from 1992–2003.” Am J Respir Crit Care Med 2007;176:277–284.
  7. Collard HR, Tino G, Noble PW, et al. “Patient experiences with pulmonary fibrosis.” Respir Med 2007;101:1350–1354.
  8. Mayberry JP, Primack SL, Muller NL. “Thoracic manifestations of systemic autoimmune diseases: radiographic and high-resolution CT findings.” RadioGraphics 2000;20:1623–1635.
  9. Nogee LM, Dunbar AE 3rd, Wert S, Askin F, Hamvas A, Whitsett JA. “Mutations in the surfactant protein C gene associated with interstitial lung disease.” Chest 2002;121:20S–21S.
  10. Rosas IO, Richards TJ, Konishi K, et al. “MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.” PLoS Med 2008;5:e93.
  11. Armanios MY, Chen JJ, Cogan JD, et al. “Telomerase mutations in families with idiopathic pulmonary fibrosis.” N Engl J Med 2007;356:1317–1326.
  12. Alder JK, Chen JJ, Lancaster L, et al. “Short telomeres are a risk factor for idiopathic pulmonary fibrosis.” Proc Natl Acad Sci U S A 2008;105:13051–13056.
  13. Seibold MA, Wise AL, Speer MC, et al. “A common MUC5B promoter polymorphism and pulmonary fibrosis.” N Engl J Med 2011;364:1503–1512.
  14. American Thoracic Society. “Idiopathic pulmonary fibrosis: diagnosis and treatment (international consensus statement).” Am J Respir Crit Care Med 2000;161:646–664.
  15. Wells AU, Behr J, Costabel U, Cottin V, Poletti V. “Triple therapy in idiopathic pulmonary fibrosis: an alarming press release.” Eur Respir J 2012;39:805–806.
  16. Nishiyama O, Kondoh Y, Kimura T, et al. “Effects of pulmonary rehabilitation in patients with IPF.” Respirology 2008;13:394–399.
Updated April 2013
This information has been approved by Gregory P. Cosgrove, MD (September 2012)
v0413